Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies
Get a quote

In silico and PBPK modelling

Working with your full project team, Sygnature’s experienced modelling and simulation team provides guidance throughout the lifetime of your project, helping to:

  • define early discovery screening cascades, interpret in vitro data and recommend options for progression to in vivo studies.
  • make recommendations of dose and dosing regimen for pharmacodynamic (PD) studies through PK and PK/PD modelling and simulation.
  • predict human PK using allometric and PBPK approaches.
  • predict efficacious pharmacological dose (integrate PK prediction with PK/PD hypothesis).
  • assess drug-drug interaction risks [metabolising enzymes (CYPs, UGTs, non-hepatic) and transporters].
  • due diligence (in-licensing evaluation or out-licensing support).

Gold standard modelling and simulation

Sygnature uses the GastroPlusTM software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data integration within the context of a virtual animal or human model. Having this in silico understanding can help us make faster and more informed development decisions. It has been identified as the number one commercially ranked program for in vitro-in vivo extrapolation and has been the focus of several publications from the FDA.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.